3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Endometrial Neoplasms
10
Ovarian Neoplasms
7
Breast Neoplasms
4
Neoplasms
2
Fallopian Tube Neoplasms
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Low Grade Serous Ovarian Carcinoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Endometrioid Adenocarcinoma
1
ER+ HER2- Advanced Breast Cancer
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Breast Diseases
1
Adenocarcinoma Of Esophagus
1
Interventions
pembrolizumab
5
Carboplatin
4
Nivolumab
3
Cisplatin
3
durvalumab
2
Paclitaxel
2
Immunohistochemistry
2
Fluorouracil
2
Bevacizumab
2
tremelimumab
1
toripalimab
1
regorafenib
1
obinutuzumab
1
naptumomab estafenatox
1
liposomal doxorubicin
1
enzalutamide
1
aflibercept
1
abiraterone
1
abemaciclib
1
Ritonavir
1
Polymerase Chain Reaction
1
Oxaliplatin
1
NEO212
1
Mass Spectrometry
1
Lopinavir
1
Leucovorin
1
Itraconazole
1
Isotretinoin
1
Ipilimumab
1
Interferon-alpha
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Squamous Cell Carcinoma
×
abemaciclib
×
Gynecologic
×
Clear all
NCT03339843
2024-03-15
MiMe-A
Jules Bordet Institute
Phase 2
Completed
85 enrolled